For research use only
| Cat No. | ABC-X0093C |
| Product Type | Overexpression Stable Cell Lines |
| Cell Type | Lymphocytes |
| Species | Human |
| Host Cell | BAF3 |
| Source Organ | Lymphatic |
| Disease | Normal |
| Storage | Liquid Nitrogen |
EML4-ALK (R1275Q) BAF3 Cell Line offers a tool for investigating ALK mutation–related signaling and testing ALK inhibitor efficacy in vitro.
Human EML4_ALK (R1275Q) BAF3 Cell Line is a stable murine pro-B cell model derived from Ba/F3 cells, engineered via lentiviral transduction to express the EML4-ALK fusion gene with a clinically significant R1275Q mutation. Transgene expression is verified by qRT-PCR, and the cells are maintained at low passage numbers (<P20). Target The EML4-ALK fusion gene is a potent oncogenic driver in non-small cell lung cancer. The R1275Q mutation enhances kinase activity and may alter responsiveness to ALK inhibitors. ALK fusions activate MAPK, PI3K-AKT, and STAT3 signaling cascades, promoting cell survival and transformation. AcceGen offers generation of stable overexpression cell lines targeting any gene of your interest. Polyclonal or monoclonal is optional based on customers' research needs.
| Species | Human |
| Cat.No | ABC-X0093C |
| Product Category | Transfected Stable Cell Lines |
| Size/Quantity | 1 vial |
| Cell Type | Lymphocytes |
| Growth Mode | Suspension |
| Shipping Info | Dry Ice |
| Growth Conditions | 37 °C, 5% CO2 |
| Source Organ | Lymphatic |
| Disease | Normal |
| Biosafety Level | 1 |
| Storage | Liquid Nitrogen |
| Product Type | Overexpression Stable Cell Lines |
| Host Cell | BAF3 |
| Quality Control | All cells test negative for mycoplasma, bacteria, yeast, and fungi. |
This model enables functional characterization of EML4-ALK fusion activity and resistance mechanisms to ALK-targeted therapies, serving as a preclinical tool for drug screening and biomarker validation.